PAVE Library: relevant scientific publications and media coverage

P. vivax information hub: EN | SPA
Vivax malaria Study Database: EN | SPA
The Partnership for Vivax Elimination: EN | SPA
Tafenoquine Roll-Out Study (TRuST): EN | SPA | PT
Peru feasibility study: EN

Publications on Radical Cure (EN):
- Malaria Journal: Challenges for achieving safe and effective radical cure of *Plasmodium vivax*: a round table discussion of the APMEN Vivax Working Group (2017)
- Towards the elimination of *Plasmodium vivax* malaria: Implementing the radical cure (2021)
- The prevention and treatment of *Plasmodium vivax* malaria (2021)
- Primaquine for *Plasmodium vivax* radical cure: What we do not know and why it matters (2021)

Publications on Radical Cure in Latin America (EN):
- Towards one standard treatment for uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* malaria: Perspectives from and for the Peruvian Amazon (2021)

Evidence on primaquine (EN):

Evidence on tafenoquine (EN):
- Pubmed: Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with *Plasmodium vivax* malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial (2021)
Additional publications on tafenoquine (EN):

- Cochrane Library: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria (2020)
- PloS Medicine: Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study (2021)
- PloS Medicine: Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study (2021)

Evidence on the G6PD test (EN):

- PloS One: Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity (2018)
- PLOS Neglected Tropical Diseases: Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil (2021)

Additional publications on the G6PD test (EN):

- Malaria Journal: Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation (2021)
- PloS: Neglected Tropical Diseases: Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study) (2021)
- Malaria Journal: Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia (2022)

EVIDENCE BRIEFS

- Pediatric treatment for P. vivax malaria: new positive data: EN | SPA | PT
- New treatment for P. vivax malaria may benefit Brazilian public health: EN | SPA | PT
- Evaluation of a point-of-care test for G6PD deficiency in Brazil: EN | PT
- Point-of-care G6PD diagnostics: EN | SPA | PT

MEDIA – ABOUT PAVE

- New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide: EN
- Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research: EN | SPA
- PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria: **EN**

**MEDIA – ABOUT P. VIVAX IN LATIN AMERICA**

- What does it take to eliminate malaria?: **PT**
- Exploring new tools for *P. vivax* elimination in Brazil: **EN | PT**
- *P. vivax* radical cure in Latin America: regional coordination to advance malaria elimination: **EN | SPA | PT**

**MEDIA – ABOUT TQ & G6PD TEST**

- Preparing the ground in the Brazilian Amazon: **PT**
- New medicine to treat malaria starts to be used in Amazonas: **EN**
- PATH and SDB announce partnership to advance diagnostic test critical for malaria treatment and elimination: **EN**

**MEDIA – REGULATORY MILESTONES**

- US FDA approves Krintafel (tafenoquine) for the radical cure of *P. vivax* malaria: **EN**
- Kozenis (tafenoquine) approved by Australian TGA for the radical cure of *P. vivax* malaria: **EN**
- Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of *P. vivax* malaria: **EN**
- New single-dose medicine to prevent relapse of *P. vivax* malaria just approved in Peru: **EN | SPA**
- Single-dose Kozenis (tafenoquine) approved for children with *Plasmodium vivax* malaria by Australian Therapeutic Goods Administration: **EN | SPA | PT**
- STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration: **EN**
- Colombia approves single-dose medicine to prevent relapse of *P. vivax* malaria: **EN | SPA | PT**

**MEDIA – FEASIBILITY STUDIES**

- First real-world use of new protocol for *P. vivax* case management in Brazil – a Health Ministry and MMV collaboration: **EN**